Bruised CVsTo broaden the scope of your thinking, I would direct you to the trading of CGC on Nasdaq which did a volue of 3.3M today, twice that of WEED traded in T.O. I would also point out that there are many US analysts covering the stock who carry a much bigger hammer than the Bay St boys. FYI, Barron's website indicates about 33 analysts covering the stock. So, I don't see much value in examining local house trade volumes unless they are block trades which means over $100,000 in that order value involving at least 10,000 shares. I would also be aware that Q1 2022 is coming up in a few weeks, so many people may not want weed stocks, and/or Canopy, in their books. There are a ton of brokers, fund managers, thematic ETFs, the retail crowd and institutional players out there, so there is absolutely no way you can know what is being talked about in the back channels. When major rebalancing is occuring there is going to be increased volatility. Lastly, regarding cash burn, there are non-core assets that can be sold or spun out separately. Another idea, not likely but possible, is the adding of a new joint venture partner to step in while the stock is at fire sale prices. Letting Canopy die a slow death is a bruise the board members don't want on their CVs, so let's hope for some good old American deal making to save the day.